ETRM : Summary for EnteroMedics Inc. - Yahoo Finance

U.S. Markets closed

EnteroMedics Inc. (ETRM)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
7.15-0.14 (-1.92%)
At close: 4:00PM EST
People also watch
PULMBIOCIDXGGLBSXGTI
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close7.29
Open7.12
Bid7.00 x 5400
Ask7.14 x 1100
Day's Range6.85 - 7.24
52 Week Range0.04 - 30.41
Volume578,459
Avg. Volume11,820,221
Market Cap30.41M
Beta2.82
PE Ratio (TTM)-0.06
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire10 days ago

    EnteroMedics Announces Publication of Three-Year Data from vBloc Diabetic Patient Study in Journal of Diabetes and Obesity

    ST. PAUL, Minn., Feb. 9, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced the publication of three-year data from the Company's VBLOC DM2 Study of vBloc® Neurometabolic Therapy in obese patients with Type 2 diabetes. The publication, entitled "Vagal Nerve Block for Improvements in Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus: Three-Year Results of the VBLOC DM2 Study," was published in the Journal of Diabetes and Obesity and is available online here.

  • PR Newswire27 days ago

    EnteroMedics Announces Closing of $19.0 Million Underwritten Public Offering and Full Exercise of Over-allotment Option

    SAINT PAUL, Minn., Jan. 23, 2017 /PRNewswire/ -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, announced the closing of an underwritten public offering of units for gross proceeds of $19.0 million, which includes the full exercise of the underwriters' over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by EnteroMedics. The offering comprised of Class A Units, priced at a public offering price of $5.31 per unit, with each unit consisting of one share of common stock and one five-year warrant (each, a "warrant") to purchase one share of common stock with an exercise price of $5.84 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock, which is convertible into 188 shares of common stock, and warrants to purchase 188 shares of common stock.

  • Biotech Movers: Illumina, Inc. (ILMN) And EnteroMedics Inc (ETRM)
    Insider Monkeylast month

    Biotech Movers: Illumina, Inc. (ILMN) And EnteroMedics Inc (ETRM)

    The JP Morgan conference took place in the biotech sector this week, and as such, we have seen an incredible amount of volatility spread across the space. The conference is probably the biggest name in the biotechnology events calendar, and it is renowned for the deals that it produces. Big-name mergers and acquisitions, takeovers, asset […]